BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 24196788)

  • 21. Human leukocyte antigen G is associated with esophageal squamous cell carcinoma progression and poor prognosis.
    Zheng J; Xu C; Chu D; Zhang X; Li J; Ji G; Hong L; Feng Q; Li X; Wu G; Du J; Zhao Q
    Immunol Lett; 2014 Sep; 161(1):13-9. PubMed ID: 24768599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment.
    Versluis MAC; Marchal S; Plat A; de Bock GH; van Hall T; de Bruyn M; Hollema H; Nijman HW
    Eur J Cancer; 2017 Nov; 86():285-295. PubMed ID: 29059634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
    Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
    Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The non-classical antigens of HLA-G and HLA-E as diagnostic and prognostic biomarkers and as therapeutic targets in transplantation and tumors.
    Seliger B
    Clin Transpl; 2013; ():465-72. PubMed ID: 25095542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
    Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
    Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Critical Assessment of the Association between HLA-G Expression by Carcinomas and Clinical Outcome.
    van de Water RB; Krijgsman D; Houvast RD; Vahrmeijer AL; Kuppen PJK
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34361031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.
    Donada M; Bonin S; Barbazza R; Pettirosso D; Stanta G
    BMC Gastroenterol; 2013 Feb; 13():36. PubMed ID: 23446022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA-G regulators in cancer medicine: an outline of key requirements.
    Zidi I; Ben Amor N
    Tumour Biol; 2011 Dec; 32(6):1071-86. PubMed ID: 21792710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
    Cascinu S; Poli D; Zaniboni A; Lonardi S; Labianca R; Sobrero A; Rosati G; Di Bartolomeo M; Scartozzi M; Zagonel V; Pella N; Banzi M; Torri V
    Eur J Cancer; 2019 Apr; 111():1-7. PubMed ID: 30797014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
    Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
    Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of HLA class I expression in patients with colorectal cancer.
    Iwayama Y; Tsuruma T; Mizuguchi T; Furuhata T; Toyota N; Matsumura M; Torigoe T; Sato N; Hirata K
    World J Surg Oncol; 2015 Feb; 13():36. PubMed ID: 25889416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.
    Levy EM; Sycz G; Arriaga JM; Barrio MM; von Euw EM; Morales SB; González M; Mordoh J; Bianchini M
    Innate Immun; 2009 Apr; 15(2):91-100. PubMed ID: 19318419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor mutational load, CD8
    Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
    Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A method for semi-automated image analysis of HLA class I tumour epithelium expression in rectal cancer.
    Krijgsman D; Van Vlierberghe RLP; Evangelou V; Vahrmeijer AL; Van de Velde CJH; Sier CFM; Kuppen PJK
    Eur J Histochem; 2019 May; 63(2):. PubMed ID: 31113192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma.
    Vora AR; Rodgers S; Parker AJ; Start R; Rees RC; Murray AK
    Br J Cancer; 1997; 76(7):836-44. PubMed ID: 9328140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of MHC class I and class II antigens in colonic carcinomas.
    Norazmi M; Hohmann AW; Skinner JM; Bradley J
    Pathology; 1989 Oct; 21(4):248-53. PubMed ID: 2633113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOXP3+ cell density in lymphoid follicles from histologically normal mucosa is a strong prognostic factor in early stage colon cancer.
    Salama P; Stewart C; Forrest C; Platell C; Iacopetta B
    Cancer Immunol Immunother; 2012 Aug; 61(8):1183-90. PubMed ID: 22210551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
    Talebian Yazdi M; van Riet S; van Schadewijk A; Fiocco M; van Hall T; Taube C; Hiemstra PS; van der Burg SH
    Oncotarget; 2016 Jan; 7(3):3477-88. PubMed ID: 26658106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer.
    Madjd Z; Spendlove I; Pinder SE; Ellis IO; Durrant LG
    Int J Cancer; 2005 Nov; 117(2):248-55. PubMed ID: 15900607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.